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Role of Interleukin 1  in Antigen-Induced 
Exacerbations of Murine Arthritis
A. A. J. van de Loo, O. J. Arntz, A. C. Bakker, 
P. L. E. M. van Lent, M. J. M. Jacobs, and 
W. B. van den Berg
From the Ihparlniunl o f Hheitmciiologw Uuivt'i'sUy Hospital 
St. Radboiui, Nijmegen, 'Ihe Netherlands
The m ech an ism  u n d erly in g  th e  ch ro n ic  a n d  in ter­
m itten t c o u rse  o f  rh e u m a to id  a r th r it is  is  n o t elu­
c id a te d I n  th e  p r e s e n t  s tu d y , th e  ro le  o f  in terleu ­
kin  1 ( IL-l)  w a s  in v e s tig a te d  in  e x a c e rb a tio n s  o f  
an tigen -in du ced  a r th r i t is  in  m ice. A f la re -u p  o f  
sm o lderin g  in flam m ation  ( w eek s  3  to  4 o f  antigen- 
in d u ced  a r th r i t is )  w a s  in du cib le  by in jec tion  o f  a  
sm all am ou n t o f  m e th y la te d  b o v in e  se ru m  albu­
m in in to  th e  h y p e rse n s itiv e  kn ee  jo in t. Im m uno- 
h is to ch em is try  s h o w e d  IL-1 e x p re ss io n  in th e  s y ­
n ovia l lining la y e r  a n d  in f o c a l  a re a s  o f  th e  
in flam ed  syn oviu m  d u r in g  th e  fla re -u p . IL-l w a s  
a lso  m e a su re d  in 1 -h o u r cu ltu re  su p e rn a ta n t o f  
syn o v ia l tis su e  taken  d u rin g  th e  f la re -u p  by a  b io ­
a ssa y . The e x p re s s io n  o f  bo th  im m uno rea c tive  
a n d  b io a c tive  IL-l in th e  h y p e rse n s itiv e  jo in t  
p e a k e d  a ro u n d  6  h o u rs  a f te r  an tigen  (2  fig  o f  
m eth y la ted  bovine se ru m  a lbu m in ) in jection  an d  
d ec lin ed  th ereafter. A n tigen  rech allen ge in du ced  
an  a c u te jo in t sw ellin g  o f  th e  a r th r it ic  jo in t  bu t not 
in the n a ive  jo in t  o f  th e  s e n s i t iz e d  m ou se, y e t  s y ­
n ovia  o f  bo th  jo in ts  p r o d u c e d  IL -l a f te r  antigen  
in jection. R em a rk a b ly , a  sin g le  in tra ven o u s in jec­
tion  o f  ra b b it an ti-IL -l cv a n d  -ß  a n tib o d ie s  1 h o u r  
b e fo re  an tigen  rech a tlen ge  n e u tra liz e d  IL-l in th e  
jo in t. Anti-IL-l trea tm en t s ig n ifica n tly  re d u c e d  th e  
an tigen -in du ced  jo in t  sw e llin g  (3 0  to  40%) bu t d id  
n ot a ffec t th e  p r o fo u n d  in flu x  o f  p o ly m o rp h o ­
n u c lea r  cells in th e  o n se t o f  th e  exa cerb a tio n . 
H o w ever , a  p r o fo u n d  r e l ie f  o f  th e  in flam m ation  
(sy n o v itis )  w a s  o b ta in e d  b y  IL -l b lo ck a d e  on d a y  
4 o f  th e  ex a cerb a tio n . C h o n d ro cy  te  p ro te o g ly c a n
w a s
berrnore,
su p p re sse d  in th e  c
in th e  anligen-rechaltenged jo in ts  w a s  s ig n ifi­
cantly d ecrea sed  in the anti-IL-1 g ro u p . We con ­
c lu d ed  th a t IL-l is  an im p o rta n t m e d ia to r  in
o f  m urine  
lion  o f  cartilage  pa th o logy> w a s w
anti-IL-1 an tibody treatm ent. (Am  J  P a th o l 1995,
146:239-249)
There is increasing evidence to suggest that the plu­
ripotent cytokine interleukin-1 (IL-1) plays an impor­
tant role in the pathogenesis of inflammatory joint dis­
eases, including rheumatoid arthritis. IL-1 has been 
identified in the synovial membrane and cartilage- 
pannus junction of arthritic joints from patients with
rheumatoid arthritis.1'"- Moreover, numerous studies 
reported a striking correlation between the IL-1 levels 
in rheumatoid synovial fluid or plasma and the dis­
ease activity in these patients. The two important 
features of arthritis, namely inflammation and carti­
lage destruction, can be attributed to local IL-1 ac­
tivity, In several mammalian species it was demon­
strated that IL-1 injected into the synovial joints 
causes an arthritic insult.15 H In vitro studies showed 
that chondrocyte proteoglycan (PG) synthesis was 
more susceptible to IL-1 than chondrocyte-mediated 
PG degradation, !) 11
To prove the importance of IL-1, 
have addressed the effect of blocking IL-1 in experi­
mental arthritis either by neutralizing IL-1 with anti­
bodies or soluble IL-1 receptors or by antagonizing 
the IL-1 binding to its receptor with IL-1 receptor an­
tagonist protein (IL-1ra) and related proteins (M20). 
These different therapeutic approaches were able to 
diminish joint inflammation and also to reduce carti­
lage destruction in collagen-induced arthritis (CIA), 
immune complex arthritis (ICA), and adjuvant arthritis
w a s  m arked ly / in the
an tigen -ch allenged  n a ive  kn ee jo in ts  su ggestin g  
th a t th is  w a s  a d ir e c t IL-1 e ffec t a s  th e  in flam ­
m ation  w a s  in sign ifican t. Anti-IL-1 trea tm en t w a s  
able to  m ain ta in  c h o n d ro c y te  p ro te o g ly c a n  syn ­
th e s is  in th e  an tigen -rech a llen ged  jo in t,  w h ich
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and in the autoimmune prone MRL/lpr mice.12“ 17 In 
murine antigen-induced arthritis (AIA), anti-IL-1 treat­
ment did not affect the acute joint inflammation 
(edema and influx of polymorphonuclear cells; PMNs) 
nor the accelerated PG breakdown, yet the marked 
chondrocyte PG synthesis inhibition was completely 
prevented.18"20 We were the first to demonstrate im­
pressive reduction both in inflammation as well as in 
cartilage destruction in established CIA using rabbit 
anti-IL-1 polyclonal antibody treatment.13 These stud­
ies at least suggest that IL-1 blockade is worth pur­
suing as a therapeutic strategy for human arthritis.
In 70% of patients with rheumatoid arthritis, the dis­
ease is characterized by an intermittent course of in­
flammation.21 In humans, a rise in plasma IL-1 ß levels 
followed the secondary flare-ups in RA, and isolated 
peripheral monocytes spontaneously produced IL-1 
during the flare-up.3,22 In the present study, experi­
ments were carried out to examine the role of IL-1 in 
the flare-up with an animal model. A flare-up of smol­
dering inflammation in the chronic phase of AIA was 
inducible in a predictable and synchronized manner 
by injection of a small amount of methylated bovine 
serum albumin (mBSA) into the hypersensitive knee 
joint.
Recently, Schwab et al23 demonstrated that 
IL-1 played a key role in the peptidoglycan- 
polysaccharide polymer reactivation of streptoccal 
cell wall-induced arthritis. It cannot be excluded that 
at least part of the flare-up reaction in this model 
was nonimmunologically mediated.24 Apart from 
peptidoglycan-polysaccharide, flare-ups can also be 
induced with cell wall-derived lipopolysaccharide 
and these fragments can directly activate macroph­
ages. In AIA, T lymphocytes, as part of the residual 
inflammation in the arthritic joints, mediated the 
antigen-induced flare-up.25,86 Antigen-stimulated T 
cells could either produce IL-1 themselves or stimu­
late IL-1 production in other cells. In rheumatoid ar­
thritis, it is still a matter of debate whether the arthritic 
process was driven by T cells, immune complexes 
(IC), or both or by nonimmunological pathways. Our 
study clearly demonstrates that IL-1 plays a key role 
in the antigen-induced exacerbation of murine arthri­
tis.
Materials and Methods
Animals
Female New Zealand White rabbits, male Wistar rats, 
and male C57BI/6 mice (Jackson Laboratories, West 
Grove, PA) were fed a standard diet and tapwater ad
libitum.
Cytokines
Murine recombinant IL-1 a and IL-1 ß were a generous 
gift from I. G. Otterness (Pfizer Central Research, Gro­
ton CT).
Generation of Rabbit Anti-Mouse 
IL-1 Antiserum
Rabbits were immunized with murine recombinant 
IL-1 a or IL-1 ß, according to the method described by 
Hogquist et al27 with some modifications. In short, 250 
(jg of IL-1 in 2.25 ml of phosphate-buffered saline 
(PBS) was emulsified with 500 pi of Imject Alum (alu­
minum hydroxide; Pierce Chemical Co., Rockford, IL). 
Each rabbit received four subcutaneous injections 
(500 pi each) of the IL-1/Alum suspension at the back 
of the animal and adjacent to each of these sites, four 
500-|jl injections of complete Freund’s adjuvant 
(C.F.A)/PBS subcutaneously. Each rabbit received 
three booster injection of 50 pg of IL-1/Alum, adjacent 
injections with incomplete Freund’s adjuvant emulsi­
fied in PBS, and additionally 5 pg of IL-1 intravenously 
every 4 to 6 weeks. Ten days after every booster, 50 
ml of blood were aspirated, coagulated, decomple­
mented at 56 C, and stored at -70 C. The neutralizing 
capacity was 300 pg of IL-1 per ml of the pooled an­
tiserum.
Purification and Characterization of 
Rabbit Anti-IL-1 Antibodies
Immunoglobulins were purified by affinity chromato­
graphic separation on a protein G sepharose 4B (al­
bumin binding region genetically deleted; Sigma 
Chemical Co., St Louis, MO) column. Immunoglobu­
lins were eluted with 0.1 mol/L glycine-hydrochloride, 
pH 3.0, and immediately neutralized with 50 mmol/L 
Tris-HCI, pH 8.0. Fractions were pooled, concen­
trated, and dialyzed against PBS at room temperature 
(RT). The anti-IL-1 antibodies showed no neutralizing 
reactivity against the other IL-1 subtype, IL-2, IL-4, 
IL-6, or tumor necrosis factor.
Generation of Rat Anti-Mouse 
IL-1 Antiserum
Wistar rats were injected subcutaneously with 50 pg 
of murine recombinant IL-1 ß emulsified in 0.5 ml of 
CFA. After 2 weeks, a booster injection was given of 
25 pg of IL-1 in 0.5 ml of CFA. Rats were bled by orbital 
punctlon at a regular basis 2 weeks after the booster 
injection.
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Flare-Up of Arthritis
Mice of 8 to 12 weeks of age received subcutaneously 
100 jjg of mBSA (Sigma), emulsified in 100 pi of CFA, 
per animal. Injections were divided over both flanks 
and footpads of the forelegs. Heat-killed (2 x  109) 
Bordetella pertussis organisms (National Institute of 
Public Health, Bilthoven, The Netherlands) was ad­
ministered intraperitoneaily as an additional adjuvant. 
Mice received two booster injections of 50 pg of 
mBSA/CFA in the neck region on day 7. Three weeks 
later, arthritis was induced by injection of 6 pi con­
taining 60 pg of mBSA in saline into the right knee joint 
cavity. At week 3 or 4 of arthritis, 0.2 to 2 pg of mBSA 
were injected intra-articularly into the arthritic joints to 
induce a flare-up of smoldering inflammation.
Joint Swelling
Mice were sedated by intraperitoneal injection of 0.25 
ml of a 4.5% chloral hydrate solution per mouse. Ap­
proximately 10 pCi 99mTechnetium pertechnetate 
(99mTc) in 0.2 ml of saline were injected subcutane­
ously in the neck region. After 15 minutes the accu­
mulation of the isotope in the knee was determined by 
external gamma counting and expressed as the ratio 
of 99mTc uptake in the inflamed to 99mTc uptake in the 
contralateral knee joint. A ratio higher than 1.1 indi­
cates joint swelling.
dine incorporation (NOB1 cells are thymidine kinase 
deficient) was determined. Detection limit of the as­
say was 0.1 pg/ml murine recombinant IL-1.1H
Assessment of Proteoglycan Synthesis
Patellae (n = 6), in a minimal amount of adjoining soft 
tissue (parts of synovium, tendon, and muscle), were 
placed in 2 ml of RPM 11640 medium with gentamicin 
(50 pg/ml) and 40 pCi [3üS]sulfate. At the end of the
3-hour incubation period, patellae were fixed in 10% 
formalin and subsequently decalcified in formic acid 
(4%), dissected, and dissolved in 0.5 ml of Lumasolve 
(Hicol, Oud-Beijerland, The Netherlands). The 3!,S 
content of each patella was measured by liquid scin­
tillation counting and expressed as counts per minute 
(cpm) or as a percentage of normal cartilage.
Histology
Standard frontal sections (7 p) of the whole knee joint, 
including both menici, cruciate ligaments, and the pa­
tella, were prepared and mounted on 2% gelatin- 
coated slides as previously described. Slides were 
stained with safranin-0 and counterstained with fast 
green. Cartilage depletion (diminished red staining) 
and inflammation were scored by a blinded observer.
IL-1 Production by Synovial Tissue
Patellae were dissected with surrounding soft tissue 
consisting of the tendon and synovium in a standard­
ized manner. Each patella was incubated in 200 pi of 
serum-free RPMI 1640 (Dutch modification) medium 
with Glutamax-1 (GIBCO BRL, Life Technologies, UK) 
for 1 hour at RT. Dilutions of these washouts were 
tested for IL-1 and IL-2 bioactivity.
Bioassay for IL-1
IL-1 activity was measured in the one-stage bioassay 
for IL-1 as described by Gearing et al28 The murine 
thymoma cell line EL-4 NOB-1 (ECACC, Porton Down, 
Salisbury, UK) was used as an IL-1-specific cell pro­
ducing IL-2 in response, in combination with the IL-
2-sensitive CTLL-2 cells (ECACC). The cells were 
plated out in concentrations of 1 x  10!iNOB1 cells per 
well and 4 x 103 CTLL cells per well in RPMI supple­
mented with 5% fetal calf serum. After 18 to 20 hour, 
0.5 pCi of [3H]thymidine (specific activity, 20 Ci/mmol; 
Dupont NEN Products, Boston, MA) were added per 
well. After 3 hours, cells were harvested and thymi­
Autoradiography
[35S]sulfate (100 pCI) (specific activity, 1200 to 1400 
Ci/mmol; Dupont NEN) was injected intraperitoneaily 
6 hours before dissection of the knee joints, After his­
tological processing, 7-p sections mounted on 0.5% 
gelatin-coated slides were dipped in K5 emulsion (Il­
ford Basildon, UK). The slides were developed and 
stained with hematoxylin and eosin after an exposure
period of several weeks. PG synthesis was scored on 
the blackening of the chondrocytes by a blinded ob­
server.
IL-1 immunostaining
Paraffin-embedded sections were mounted on 2% 
gelatin-coated slides, deparaffinized in xylene for 5 
minutes twice, and rehydrated to deionized water. En­
dogenous peroxidase activity was blocked with 1% 
A  in PBS for 20 minutes at RT. Slides were then 
rinsed in water and incubated overnight with the pri­
mary antibody, rat anti-IL-1 ß antiserum, or Irrelevant 
rat antibody, diluted 1/150 In PBS plus 5% nonfat dry
242 van de Loo et al
AJ F January ¡995. Vol. ¡46, No. 1
milk at 4 C in a humidified box. Were washed in ex­
cess PBS plus 0.1 % Tween 20, three times for 10 min­
utes each time and incubated with biotinylated sec­
ondary antibody, rabbit anti-rat antibody diluted 
1/200 in PBS plus 5% nonfat dry milk and 2% normal 
mouse serum for 1 hour at RT. They were then washed 
again in PBS/Tween 20 three times for 10 minutes 
each time. Avidin-biotin-peroxidase conjugated com­
plex was prepared according to the directions for 
preparation (Vectastain ABC kit; Vector Laboratories, 
Burlingame, CA). Slides were incubated with the ABC 
reagent diluted in PBS plus 5% nonfat dry milk for 30 
minutes at RT and washed again in PBS/Tween 20. 
Slides were then developed with 0.5 mg/ml dia- 
minibenzidine in Tris-HCI, pH 7.6, and 0.02% H20 2 for 
10 minutes and counterstained with hematoxylin for 
15 seconds. Anti-IL-1 antiserum was preincubated on 
IL-1ß-coated plates, eight times for 20 minutes each 
at RT, or normal rat serum was used as a negative 
control. For control of IL-1 ß specificity, antiserum was 
preincubated on IL-1 a- or BSA-coated plates.
Treatment of Mice with Anti-IL-1 
Antibodies
Mice received 200 pi of a standard dose of 1 mg of 
purified rabbit anti-IL-1 a antibody and 1 mg of anti- 
IL-1/3 antibody intravenously into the orbita plexus 1 
hour before induction of the flare-up. These antibod­
ies had an excellent half-life of more than 3 days in the 
blood circulation as was assessed by enzyme-linked 
immunosorbent assay. Total neutralizing capacity of 
the received dose was approximately 32 ng of both 
subtypes of IL-1 as was tested in the IL-1 bioassay 
(NOB-1) and blocked the effect of 1 ng of IL-1 a or-ß 
on PG synthesis completely and that of 10 ng of IL-1 
partially in vivo (not shown). Normal rabbit IgGs or 
polyclonal anti-ovalbumin antibodies served as con­
trols for nonspecific effects of the treatment.
Results 
IL-1 Expression in Antigen-Rechallenged 
Knee Joints of Chronic Arthritis
At the time of antigen rechallenge, week 3 of AIA, 
avidin-biotin immunohistochemistry with rat anti­
serum to IL-1 ß failed to demonstrate IL-1 on whole 
knee joint sections (not shown). A single intra- 
articular injection of a small amount of antigen (2 pg 
of mBSA) caused a transient expression of cell- 
associated IL-1 ß. The number of IL-1 ß-positive cells 
was small in the joint sections taken at 1 hour, high at
3 hours, low but still evident at 6 and 12 hours, and 
absent at 24 hours after the antigen rechallenge (not 
shown). The IL-1 ß signal was predominantly localized 
in the synovial lining layer and frequently in focal ar­
eas in the inflamed synovium (Figure 1). No immuno- 
staining was evident with normal rat serum or with 
anti-IL-1 ß antiserum preincubated on microtiter 
plates coated with murine recombinant IL-1 ß (Figure 
1). In some sections, chondrocytes and the exudate 
PMNs were nonspecifically stained.
A single intra-articular injection of mBSA into hy­
persensitive joints (week 3 of AIA) caused a dose- 
related joint swelling at 6 hours (Figure 2). Synovial 
tissue culture supernatants demonstrated increased 
levels of IL-1 bioactivity 6 hours after antigen rechal­
lenge in the tested dose range of 0.06 to 2 pg of mBSA 
(Figure 2). Time course experiments demonstrated a 
rapid onset of joint swelling increasing at least up to 
24 hours after antigen (2 pg mBSA) rechallenge of AIA 
(Figure 3). The level of bioactive IL-1 in synovial tissue 
culture supernatants of arthritic joints was high 3 and 
6 hours after antigen rechallenge (Figure 3), The ex­
pression of IL-1 was more transient compared with 
joint swelling. At 24 hours after antigen injection, IL-1 
released by the synovial tissue was low yet joints were 
profoundly swollen. Joint swelling was not inducible 
with 2 pg of mBSA injected into naive joints of sen­
sitized animals (Figure 3). Interestingly, the antigen- 
challenged naive joints released IL-1 in levels and 
time course comparable with the rechallenged ar­
thritic joints (Figure 3).
Role of IL-1 in the Antigen-Induced 
Exacerbation of Chronic Joint 
Inflammation
At the time of antigen rechallenge, week 3 of AIA, 
swelling of the arthritic joints subsided and the in­
flammatory exudate cells disappeared, but joints had 
a mild ongoing synovitis (Table 1). Intra-articular in­
jection of 2 pg of mBSA into the arthritic joints caused 
an acute transient joint swelling (Table 1 ). On day 2 of 
the flare-up a Tc ratio of 1.22 ± 0.14 was measured 
(not shown). The same antigen dose injected into the 
naive contralateral joints of these arthritic animals did 
not cause joint swelling (Table 1).
To investigate the role of de novo synthesized IL-1, 
neutralizing polyclonal anti-IL-1 a and -ß antibodies 
were injected intravenously 1 hour before antigen re­
challenge. Blocking IL-1 decreased joint swelling by 
29% at 6 hours and significantly reduced joint swell­
ing by 41% at 24 hours after antigen rechallenge as 
compared with untreated mice (Table 1). This was a
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Figure 1. Innniinoperoxklase localization o ftrbo le  k m v  jo in t sections showing evils stained for  IL-Iß { magnification t x ¿50) in foca i arcas o f  the 
inflamed synovium  (A) a n d  in the synovia) lining layer {B). Antigen ( J  / tg o f  mBSA) was injected lut nvarl ieu iarly al treek ,í o f  AfA a n d  ja i  nis 
¿rere dissected J hours thereafter. Serial sections stabled irith nonna! rat serum (C) or with anti II. /ß anlisenun [ w in e  t tinned on l i  Iß < tuned 
microliter plates ( D ) senvcl as negative controls. (V. cartilage; i% exúdate, ß \  joint space; /„ lining layer; S, synoriuni,
consistent finding in all experiments: mean joint swell­
ing of 1.60 ± 0.21 in the untreated mice (n = 47), 1.52 
± 0.24 in the normal rabbit IgG-treated mice (n = 68), 
and 1.37 ± 0.29 in the anti-IL-1-treated mice (n = 75) 
on day 1 after antigen rechallenge.
Antigen injection also caused a marked influx of 
polymorphonuclear neutrophils (PMN) into the cavity 
and exacerbated the ongoing synovitis in the hyper­
sensitive joint (Table 1 ). A moderate inflammation was 
inducible in the naive contralateral joints of these sen­
sitized animals with the same antigen dose (2 pg of 
mBSA) used (Table 1).
Anti-IL-1 a and -ß antibody pretreatment had no ef­
fect on the number of inflammatory cells (PMN) in the 
6- and 24-hour exudate and on the extent of the sy­
novitis at these time points (Table 1). A marked ame­
lioration of the synovitis was observed on day 4 after 
antigen rechallenge in the anti-IL-1-treated group 
(Table 1 and Figure 4). This was a consistent finding 
in three out of a total of four experiments. Synovitis in 
the normal rabbit IgG-treated mice (1.55 ± 0.69, n = 
21) was significantly higher than in the anti-IL-1 - 
treated mice (0.63 ± 0.23, a reduction of 59%).
Role of IL-1 in the Flare-Up Related 
Cartilage Pathology
the first weeks of AIA, returned to a normal rate at
was evident on day 1 (- 
antigen rechallenge in
23%) aftor
measured by [
2). Pretreatment of mice with anti-IL-1 antibodies
to occur (Table 2). Autoradiography of whole knee 
joint sections also demonstrated reduced [ 
incorporation by chondrocytes in the cartilage of ar
re
challenge (Table 3 and Figure 5). Blocking IL-1 ac 
tivity with antibodies significantly enhanced PG 
synthesis in antigen-rechallenged mice (Table 3 and
a *
the naive contralateral joints of these mice also re­
sulted in a significant suppression of PG synthesis on 
day 1 (Tables 2 and 3).
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Figure 2. Dose-related jo in t swelling a n d  IL-1 production iti antigen- 
rechallenged hypersensitive knee jo in ts . Ant igei i (0 .0 6  to 2  ¡tg o f  
mBSA ) was injected intra-articidarly into arthritic joints at week 3  o f  
AIA. Joint swelling was measured 6  hours after the antigen recluti- 
leuge by external gam m a counting o f i}t>mTc uptake . Values represent 
the mean ratio o f  arthritic (10 over the naive contralateral jo in t ( L ) 
±  SD o f  sei v  u ¿mim a Is.  A 1/80 dilution of c ulta re supe m a ta  /1 ts o f  sy- 
n ovia I tissue taken 6  hours after antigen rechallenge teas tested fo r  
IL- I by a cell proliferation assay. Values represent the mean stimula­
tion index  ±  SD o f  six individual synovia. Highest signal (SD is com­
parable with the response to 4 pg/m l IL-1 in the assay  ( 10,000 cpm). 
Statistical significance was tested hy using the Wilcoxon ’s rank sum 
tests. < 0 .05  was co)isidered significant.
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Figure 3. ‘time-related changes in joint stveiling a n d  IL-1 ¡mniuclion 
in antigen rechallenged hy/iersensr’titv knee joints  ( A ) a n d  in naive 
join ts ( f  si V/.S/7 izi >d mice ( B ) .  .*1111 igei t (2  /  tg t f  mBSA ) was i i iject ed  
intra articitlarly a n d  both jo in t swelling a n d  IL-1 production hy the 
synovia! t isst tes u'as n let is u red (as described in Figure 2 ) at several 
time points thereafter in six animals each , Statistical sigilificance was 
testet/ by itsi/tg (be \Vih■ im m's rank sum tests .  *V < 0.05 u'as cotisid­
ered significant.
Enhanced PG degradation (-59%) was found in 
the hypersensitive joints 1 day after antigen rechal­
lenge as was measured on [3SS]sulfate prelabeled 
patellar cartilage in vivo (Table 2). The accelerated 
degradation could be significantly reduced by anti- 
IL-1 treatment but was still remarkable (-37% Table 
2).
Histology taken at week 4, but not at week 3, of AIA 
showed full recovery of the cartilage matrices (Figure
4). Antigen (2 pg of mBSA) rechallenge caused se­
vere PG depletion of the cartilage matrices as was 
shown on safranin-O-stained whole knee joint sec­
tions (Table 3 and Figure 4). Pretreatment with anti- 
IL-1 antibodies, but not with control IgG, significantly 
ameliorated the cartilage pathology on day 4 of the 
antigen-induced exacerbation (Table 3 and Figure 4), 
Anti-IL-1 a and -ß pretreatment completely prevented 
the antigen-induced cartilage depletion in the hyper­
sensitive joints in four of five experiments. Antigen 
injection into the naive contralateral joints of the ar­
thritic mice caused only minor cartilage depletion 
(Table 3).
1
Discussion
This study clearly demonstrates that IL-1 is an impor­
tant determinant in antigen-induced exacerbations of 
murine arthritis. In the conducted experiments, pre­
treatment of mice with rabbit polyclonal antibodies 
directed against murine recombinant IL-1 a and IL-1 ß 
markedly alleviated joint swelling and ameliorated 
cartilage pathology of the antigen-rechallenged 
joints.
Using avidin-biotin immunohistochemlstry, we 
showed IL-1 ß expression in the synovium of antigen- 
rechallenged joints, predominantly located in the lin­
ing layer and in distinct cell clusters in the sublining 
layer and in single cells sparsely distributed in the 
deeper area. An identical localization was also found 
in synovial membranes of rheumatoid arthritis for 
IL-1 a and IL-1ß.1'2The expression of IL-1 ra was iden­
tical to IL-1 in the rheumatoid synovium although the 
number of positive cells was considerably smaller. 
We found identical kinetics for the expression of both 
bioactive and immunoreactive IL-1 in hypersensitive 
joints after antigen rechallenge. This indicates that 
IL-1 inhibitors (eg, IL-1 ra), although they may be pro­
duced, were not responsible for the transient expres­
sion of bioactive IL-1 in the flare-up.
IL-1 was inducible in both virgin and hypersensitive 
joints of sensitized mice but not in joints of normal 
mice.18 This shows that the stimulation of IL-1 was not 
a property of the antigen but that either antigen- 
specific T lymphocytes or immunoglobulins were in­
volved. IL-1 production in rheumatoid synovial mem­
branes was considerably higher in membranes 
possessing lymphocyte aggregates compared with 
membranes with a disperse infiltrate.29 These focal 
areas are composed of B cells, plasma cells, and 
CD4'h T cells In the center and macrophages at the 
periphery. Not only T helper type 2 cells but also B 
cells, as almost all accessory cells (eg, macroph­
ages), can produce IL-1. We did not quantitatively
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compare the IL-1 production in antigen challenged 
naive and hypersensitive joints, but only in the latter 
did we find distinct staining of cell clusters.
The antigen dose used for the flare-up of AIA did 
not induce inflammation when injected in normal knee 
joints of sensitized mice. This suggests that the 
antigen-induced IL-1 production was too low to in­
duce joint inflammation in normal joints. This is in 
agreement with a previous study of ours in which we
induce joint swelling or cell exudate in naive joints but 
induced a brief flare-up of the inflammation in arthritic 
joints of AIA.0,30 A highly likely explanation for this 
hypersensitive state could be the increased expres-
adhesion molecules) in the inflamed synovium,'"
In the present study we found, using anti-IL-1« and 
-ß antibodies, that the cell exudate and the joint swell­
ing for the greater part (60 to 70%) were not IL-1 me­
diated in the antigen-induced exacerbation of AIA, 
and this suggests that other mediators are involved in 
this process. Possible candidates are T cell-derived 
mediators. Evidence was presented that CD41 T cells 
are mediating the antigen-induced exacerbation of 
murine a r th r i t i s . I t  was concluded from the full 
blockade of the flare-up by anti-la (histocompatibility 
type II antigens) antibodies that antigen presentation 
was of importance.s(i Although IL-1 is capable of ac-
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i Normal rabbit antibodies (NRS) or anti-IL-1 a and -ß antibodies injected 1 hour before antigen rechallenge.
* [35S]Sulfate incorporation into patellar cartilage ex vivo. Values in parentheses indicate the Inhibition of PG synthesis as a percentage of 
the unchallenged joint. Representative of two experiments.
§ p t ig ]3 U|fa te  content in patellar cartilage. [a5S]Sulfate was injected subcutaneously 24 hours before antigen injection.
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Table 3. Histological Analysis o f the Anti-IL-1 Treatment Effect on PG Synthesis a nd  Cartilage PG Depletion in
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N P < 0.05 was considered significant, as tested by using the Wilcoxon's rank sum tests,
tivating lymphocytes, we found that the IL-1-induced 
exacerbation of AIA was not lymphocyte mediated, 
and this implies that the antigen- and IL-1-induced 
flare-up are different from each other.30 Evidence is 
emerging that IL-1 does not play a prominent role in 
antigen-induced T cell activation.33'3'1 We selectively 
blocked the Th1-derived IL-2 and the Th2-derived 
IL-4 with antibodies and this markedly reduced joint 
swelling, cell exudate, and infiltrate during the 
antigen-induced flare-up.32 Co-injection of large 
amounts of IL-2 or IL-4 with the antigen significantly 
enhanced cell exudate. We concluded that the T cell- 
derived cytokines IL-2 and IL-4 are acting as proin- 
flammatory cytokines during antigen-induced exac­
erbation of AIA.
Schwab et al36 demonstrated that reactivation of 
streptococcal cell wall-induced arthritis by the T cell 
superantigen, toxic shock syndrome toxin 1, was nei­
ther IL-1 nor tumor necrosis factor-« dependent, in 
contrast with the peptidoglycan polysaccharide re­
activation, suggesting that the latter was not solely T
cell mediated. A more important role of IL-1 was found 
in IC-mediated inflammations.-m37 Recently we de­
veloped an IC-mediated arthritis model (ICA) by pas­
sive immunization in the mouse.14 In this model, IL-1 
and complement activation acted synergislically in 
the onset of inflammation. Striking anti-inflammatory 
effects with anti-IL-1 antibodies or IL-1 receptor an­
tagonist protein (IL-1 ra) were also found in CIA, even 
when treatment was started in already established 
disease.13 In contrast, anti-IL-1 treatment had no ef­
fect on the onset of AIA.18 20 CIA is probably more IC 
than T cell mediated.38,39 For instance, although CIA 
could be transferred by T cells or IC, a combination 
resulted in a more pronounced inflammation,40 How­
ever, AIA and the subsequent hypersensitive state of 
the joints could be transferred with antigen (mBSA)- 
-specific T cells to naive recipients.41 Up until now, we 
were unable to transfer the disease (AIA) by B cells 
or immunoglobulins (unpublished data). The impor­
tance of IL-1 could be related to the type or the site 
of the inflammation,16'37
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Antigen rechallenge of the hypersensitive joints in­
duced a marked inhibition of chondrocyte PG syn­
thesis for at least 4 days. This was not a property of 
the antigen as PG synthesis suppression was not in­
ducible in joints of nonimmune mice.18 The flare-up of 
the inflammation was also not responsible for the sup­
pression of the chondrocyte synthetic function for two 
reasons. First, antigen injection into naive joints of 
sensitized mice induced both IL-1 production and in­
hibition of PG synthesis without a significant joint in­
flammation. Second, blocking IL-1 with neutralizing 
anti-IL-1 a and -ß antibodies protected the chondro­
cyte synthetic function without affecting the onset of 
the flare-up. We previously demonstrated a key role 
of IL-1 in the inhibition of PG synthesis in several mu­
rine arthritis models, ie, CIA, AIA, and ICA.13,1H<1!Mi?
The enhanced cartilage degradation in the 
antigen-challenged arthritic joints was, for approxi­
mately 50%, IL-1 mediated. In ICA and CIA, the anti- 
IL-1 also significantly reduced PG degradation, but 
this was probably related to the alleviation of joint in­
flammation.13'“13 A more likely explanation for the pro­
tective effect of anti-IL-1 treatment on the flare-up is 
a higher vulnerability for IL-1-induced degradation of 
cartilage in the recovery phase of arthritis (manu­
script in preparation). Pelletier et al44 presented evi­
dence for an enhanced number of IL-1 receptors on 
chondrocytes in human osteoarthritic cartilage and 
showed that the IL-1 required for half-maximal met- 
alloproteinase stimulation was three to four times 
lower compared with normal cartilage.
Protection of the chondrocyte synthetic function 
and reduction of the enhanced PG degradation prob­
ably resulted in the observed amelioration of the car­
tilage pathology on day 4 after antigen rechallenge. 
Mini-osmotic pumps releasing 30 pg of IL-1 ra per 
hour into the peritoneal cavity from day 2 before an­
tigen rechallenge up to 7 days thereafter verified the 
anti-IL-1 antibody effects (not shown).
Another impressive effect of the anti-IL-1 treatment 
was the reduction in the synovial thickness (hyper­
plasia) on day 4 of the exacerbation. IL-1 is a potent 
growth factor for synovial fibroblasts, which can ex­
plain this anti-IL-1 effect.46 Synoviocytes can actively 
participate in the local hypersensitivity for a number 
of reasons. First, synovial fibroblasts (synoviocytes) 
are accessory cells by their capacity of antigen pre­
sentation and IL-1 expression,4tv1/Second, adhesion 
molecules can be induced by cytokines on type B 
synoviocytes, which may facilitate leukocyte recruit- 
ment.4H'4i) Moreover, unrestricted synoviocyte prolif­
eration caused arthritis in animals and synovial tissue 
implants caused cartilage destruction.!,t)-,>1 There­
fore, the reduction of the synovial hyperplasia in the 
antigen-rechallenged joints could be responsible for 
the amelioration of arthritis,
This study indicates that IL-1 is involved as key 
mediator in the pathological changes of cartilage, riot 
only in IC-mediated inflammation but also in T cell- 
mediated inflammation. Our study strengthens the 
need for additional research of the role of IL-1 even 
when iL-1 is not involved in the onset of inflammation.
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